GC Genome Q1 2026: Revenue +9%, Net Profit +174%, Cash 37.7B Won

Revenue 7.44B KRW (+9.1% YoY)
Operating profit 0.14B KRW (turned positive)
Net profit 0.81B KRW (+174% YoY)
EPS 34 KRW (vs 15 KRW)
Cash & cash equivalents 37.66B KRW; negative net debt (-28.6B); strong financial position
Transferred 20B KRW from capital surplus to retained earnings for shareholder value
R&D expenses 1.54B KRW (20.7% of revenue); 52 patents
Overseas license-out: GC Labtech (USA) for iCanSearch, MP Group (Thailand) for GenomeHealth
New product pipeline: AI-based early cancer screening (iCanSearch), NIPT (G-NIPT), HRD test
Post-IPO first year deviation (revenue -11%, operating profit -76%) but Q1 2026 shows improvement